Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow PLIANT THERAPEUTICS, INC.

Get SEC filing alerts via email and in your feed for PLIANT THERAPEUTICS, INC.

PLRX

PLIANT THERAPEUTICS, INC.

About PLIANT THERAPEUTICS, INC.

Pliant Therapeutics is a biopharmaceutical company focused on discovering and developing therapies for fibrotic diseases. Its core pipeline includes oral small molecules targeting integrins to treat idiopathic pulmonary fibrosis, primary sclerosing cholangitis, and resistant solid tumors. The company leverages proprietary biology, medicinal chemistry, and biomarker tools to de-risk and accelerate fibrosis drug development for orphan and high unmet need indications.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from PLIANT THERAPEUTICS, INC.

1
1
PLIANT THERAPEUTICS, INC. Pliant Therapeutics Reports $20M Net Loss in Q1 2026, Down from $56.2M Last Year

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
PLIANT THERAPEUTICS, INC. Pliant Therapeutics Reports Fiscal Year 2025 Results, Focuses on Oncology Program

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
PLIANT THERAPEUTICS, INC. Pliant Therapeutics Reports $26.3 Million Net Loss in Q3 2025, Down from $57.8 Million Last Year

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
PLIANT THERAPEUTICS, INC. Pliant Therapeutics Reports $43.3 Million Net Loss in Q2 2025, Focuses on Oncology Program

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
PLIANT THERAPEUTICS, INC. Pliant Therapeutics Reports $56.2 Million Net Loss in Q1 2025, Announces Workforce Reduction

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
PLIANT THERAPEUTICS, INC. Pliant Therapeutics Reports $210.3 Million Net Loss and Nil Revenue for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
PLIANT THERAPEUTICS, INC. Pliant Therapeutics Reports Significant Financial Challenges, Net Loss of $57.8 Million in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments